Boyd Taylor 4

What Happened

• Boyd Taylor, Chief Business Officer of Avalo Therapeutics (AVTX), received a derivative award on February 26, 2026 covering 95,000 shares. The Form 4 records the acquisition price as $0.00, indicating this was a grant/option award rather than an open-market purchase or sale. No cash was paid as part of this reported transaction.

Key Details

• Transaction date: 2026-02-26 (Form filed 2026-03-02).
• Security/amount: Derivative award covering 95,000 shares; reported price $0.00 (award/grant).
• Vesting: 25% vests on February 26, 2027; the remaining 75% vests in equal monthly installments over the following three years (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: No late-filing flag noted in the provided information.
• Note: This is an award (derivative/option grant). It does not represent an immediate sale or open-market purchase — future shares will only be received as vesting and any exercise conditions are met.

Context: For retail investors, awards like this are common for executives as part of compensation and retention. They indicate potential future dilution if options are exercised and vested, but do not by themselves represent a purchase (bullish signal) or sale (bearish signal).